Age/Sex | 6/M | 10/M | 6/M | 2/F | 26/F | 6/M | 31/F | 14/M |
---|---|---|---|---|---|---|---|---|
Post Allo-HSCT Relapse(Months) | 24 | 9 | 29 | 7 | 1 | 2 | 3 | 3.5 |
Blasts in BM(%) | 68 | 75 | 16 | 69 | 1 | 34.5 | 59 | 7.5 |
Follow-up Day | 345 | 218 | 167 | 124 | 119 | 99 | 90 | 83 |
Dose/kg | 1x106 | 1x106 1x105 | 3x105 | 3x105 | 3x105 | 1x105 | 1x105 2x105 | 3x105 |
CAR-T Cells | Donor | Auto | Auto | Donor | Donor | Donor | Auto | Auto |
CRS Grade | IV | III | III | I | I | I | II | I |
GVHD after CAR-T | No | No | No | aGVHD(II) | No | Mild cGVHD | No | No |
Initial Response | CR | CR | CR | NR | CR | CR | CR | CR |
Outcome | Relapse on day 167 | 2nd allo-HSCT Remain CR | Relapse on day 98 | Other therapy | Remain CR | Remain CR | MLL-AF4 0.02% on day 75 | Remain CR |